Trials / Completed
CompletedNCT07509905
TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.
Detailed description
Chemotherapy-induced nausea and vomiting significantly impacts the quality of life for 70%-80% of cancer patients receiving chemotherapy. The P6 acupressure point is traditionally used to relieve these symptoms and has shown benefits in pain relief and other conditions. If studies on Transcutaneous electrical acupoint stimulation yield positive results, it could be integrated as an effective method to manage chemotherapy-induced nausea and vomiting, enhancing patient comfort and treatment outcomes while potentially reducing the need for dosage adjustments. This study aims to address gaps in current treatments, improving management and quality of life for affected cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Transcutaneous electrical nerve stimulation | The acupoints were wiped with a moist cotton swab and then connected to the anode and cathode of the electrical stimulation generator through an electrode patch placed on the skin surface. Continuous wave form mode was selected, and then the electric current produced continuous stimulation on the acupoints. Stimulation frequency was set at 4 Hz, and the default value was set as 10 mA, which was twice the sensory threshold (5 mA). The intensity was adjusted every 10 min to keep the patients comfortable, and its actual value ranged from 7 to 15 mA. |
| DRUG | Antiemetic | the drug is being taken once a day for 72 hours after introducing chemotherapy |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2026-01-20
- Completion
- 2026-02-18
- First posted
- 2026-04-03
- Last updated
- 2026-04-03
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07509905. Inclusion in this directory is not an endorsement.